GPT and metabolic dysfunction-associated steatotic liver disease: The stratified analysis on the basis of etiology in this study demonstrated silymarin's greater effectiveness in HBV, HCV, and NAFLD subgroups, with ALT normalization significantly higher in HBV (23.1% vs. 10.0%, p = 0.038) and lower ALT levels in HCV (67.58 ± 22.41 U/L vs. 80.91 ± 23.64 U/L, p = 0.014) and NAFLD (42.43 ± 16.90 U/L vs. 67.92 ± 30.47 U/L, p = 0.013).